The objective of this study is to assess the safety and feasibility of allogeneic adipose tissue-derived mesenchymal stem cells (ASCs) injected into the lacrimal gland in a smaller groups of 7 patients with Aqueous Deficient Dry Eye Disease (ADDE)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pain at injection site: grade
Timeframe: 4 months after treatment
Infection at injection site
Timeframe: 4 months after treatment
Bleeding at injection site
Timeframe: 4 months after treatment
Eyelid function disorder
Timeframe: 4 months after treatment
Periorbital edema
Timeframe: 4 months after treatment
Ocular discomfort
Timeframe: 4 months after treatment
Flu-like symptoms
Timeframe: 4 months after treatment
Fever
Timeframe: 4 months after treatment